Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Canadian Cancer Trials Group
Canadian Cancer Trials Group
University of Michigan Rogel Cancer Center
University of Cologne
University of Miami
City of Hope Medical Center
International Extranodal Lymphoma Study Group (IELSG)
Sun Yat-sen University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Sun Yat-sen University
South Plains Oncology Consortium
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Takeda
Fred Hutchinson Cancer Center
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
Roswell Park Cancer Institute
University of Miami
Children's Hospital of Philadelphia
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Massachusetts General Hospital
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
Northside Hospital, Inc.
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
University Hospital, Limoges